L. Xu, Y. -Y. Tan, L. Wu, L -L. Wang, H. Li, J.-Q. Ding and S.-D. Chen Pages 1412 - 1418 ( 7 )
Cell-replacement therapy using Parkinson’s disease (PD) specific induced pluripotent stem cell (iPSC) holds great promise in treating PD. However, the problem of iPSC safety and efficiency restrict its clinical application. Meanwhile the requirement of skin biopsy for fibroblast will increase the risk of complication. In the past few years, the advances of iPSC technology in efficiency, cell resource, safety and cell culture have made it possible to use the derivatives of iPSCs to clinical PD treatment. This review will summarize these progresses of iPSC technique in this fast-moving community.
iPSC, Parkinson's disease, reprogramming, treatment.
Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Rui Jin Er Road, Shanghai 200025, China.